MX375024B - Tratamiento de alopecia areata. - Google Patents

Tratamiento de alopecia areata.

Info

Publication number
MX375024B
MX375024B MX2018003332A MX2018003332A MX375024B MX 375024 B MX375024 B MX 375024B MX 2018003332 A MX2018003332 A MX 2018003332A MX 2018003332 A MX2018003332 A MX 2018003332A MX 375024 B MX375024 B MX 375024B
Authority
MX
Mexico
Prior art keywords
alopecia areata
treatment
oxopropanenitrile
diazaspiro
octan
Prior art date
Application number
MX2018003332A
Other languages
English (en)
Spanish (es)
Other versions
MX2018003332A (es
Inventor
Atsuo Tanimoto
Michael Sierra
Tord Labuda
Yuichi Shinozaki
Original Assignee
Japan Tobacco Inc
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2015190849A external-priority patent/JP2017066061A/ja
Application filed by Japan Tobacco Inc, Leo Pharma As filed Critical Japan Tobacco Inc
Publication of MX2018003332A publication Critical patent/MX2018003332A/es
Publication of MX375024B publication Critical patent/MX375024B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2018003332A 2015-09-24 2016-09-22 Tratamiento de alopecia areata. MX375024B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15186644 2015-09-24
JP2015190849A JP2017066061A (ja) 2015-09-29 2015-09-29 円形脱毛症治療剤
PCT/EP2016/072531 WO2017050891A1 (en) 2015-09-24 2016-09-22 Treatment of alopecia areata

Publications (2)

Publication Number Publication Date
MX2018003332A MX2018003332A (es) 2018-08-16
MX375024B true MX375024B (es) 2025-03-06

Family

ID=57047187

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003332A MX375024B (es) 2015-09-24 2016-09-22 Tratamiento de alopecia areata.

Country Status (27)

Country Link
US (3) US20180263986A1 (enExample)
EP (1) EP3352734B1 (enExample)
JP (1) JP6776345B2 (enExample)
KR (1) KR102728341B1 (enExample)
CN (1) CN108135834B (enExample)
AU (3) AU2016325388A1 (enExample)
BR (1) BR112018005771B1 (enExample)
CA (1) CA2998972A1 (enExample)
CY (1) CY1122837T1 (enExample)
DK (1) DK3352734T3 (enExample)
ES (1) ES2779762T3 (enExample)
HR (1) HRP20200472T1 (enExample)
HU (1) HUE049052T2 (enExample)
IL (3) IL312861A (enExample)
LT (1) LT3352734T (enExample)
MX (1) MX375024B (enExample)
MY (1) MY196541A (enExample)
PL (1) PL3352734T3 (enExample)
PT (1) PT3352734T (enExample)
RS (1) RS60365B1 (enExample)
RU (1) RU2754997C2 (enExample)
SG (1) SG10202111361TA (enExample)
SI (1) SI3352734T1 (enExample)
TW (1) TWI720022B (enExample)
UA (1) UA124192C2 (enExample)
WO (1) WO2017050891A1 (enExample)
ZA (1) ZA201801722B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119367282A (zh) * 2019-12-27 2025-01-28 乐敦制药株式会社 水性组合物
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
JP2025514747A (ja) 2022-04-20 2025-05-09 レオ ファーマ アクティーゼルスカブ 前頭部線維性脱毛症の治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤

Also Published As

Publication number Publication date
JP2018528238A (ja) 2018-09-27
SG10202111361TA (en) 2021-12-30
UA124192C2 (uk) 2021-08-04
LT3352734T (lt) 2020-04-10
RS60365B1 (sr) 2020-07-31
DK3352734T3 (da) 2020-03-30
ZA201801722B (en) 2025-06-25
AU2016325388A1 (en) 2018-03-29
EP3352734B1 (en) 2020-01-15
NZ740690A (en) 2024-11-29
ES2779762T3 (es) 2020-08-19
RU2754997C2 (ru) 2021-09-08
EP3352734A1 (en) 2018-08-01
IL298520A (en) 2023-01-01
SI3352734T1 (sl) 2020-07-31
BR112018005771B1 (pt) 2023-12-05
HUE049052T2 (hu) 2020-09-28
MY196541A (en) 2023-04-19
CA2998972A1 (en) 2017-03-30
CN108135834A (zh) 2018-06-08
US20180263986A1 (en) 2018-09-20
KR20180054767A (ko) 2018-05-24
IL312861A (en) 2024-07-01
AU2024204716B2 (en) 2026-06-11
AU2022202508A1 (en) 2022-05-12
HRP20200472T1 (hr) 2020-09-18
JP6776345B2 (ja) 2020-10-28
US20240398809A1 (en) 2024-12-05
RU2018114922A (ru) 2019-10-28
MX2018003332A (es) 2018-08-16
PL3352734T3 (pl) 2020-08-24
TWI720022B (zh) 2021-03-01
CN108135834B (zh) 2021-07-27
WO2017050891A1 (en) 2017-03-30
PT3352734T (pt) 2020-03-31
RU2018114922A3 (enExample) 2019-12-11
US20220088020A1 (en) 2022-03-24
BR112018005771A2 (pt) 2018-10-09
AU2024204716A1 (en) 2024-07-25
KR102728341B1 (ko) 2024-11-11
HK1257770A1 (en) 2019-10-25
TW201717955A (zh) 2017-06-01
IL257918A (en) 2018-05-31
CY1122837T1 (el) 2021-05-05

Similar Documents

Publication Publication Date Title
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MX2016009403A (es) Compuestos heterociclicos.
PH12016501570B1 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
EA201692003A1 (ru) Макроциклические производные пиримидина
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX372997B (es) Compuestos de aminopirimidina como inhibidores de jak.
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
EA201692000A1 (ru) Макроциклические производные пиридина
CL2016001895A1 (es) Compuestos
MX373307B (es) Compuestos de biaril-amida como inhibidores de cinasa.
EA201492112A1 (ru) ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА
MY193728A (en) Muscarinic receptor agonists
CY1126388T1 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX363436B (es) Derivados de oxazolidin-2-ona-pirimidina.
CY1122837T1 (el) Θεραπεια της γυροειδους αλωπεκιας
EA201990046A1 (ru) Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета
GB2519470A (en) Bicyclic aza compounds as muscarinic M1 receptor agonists

Legal Events

Date Code Title Description
FG Grant or registration